Our work

Impact for the most neglected

At the moment my daughter is doing well, the capsules are working good and are easy to use after the nurse showed me how to use them.
Jacklyne Kabakama
23, with her daughter in Kihara village, a rural area near Fort Portal, Uganda, speaking of the 2-in-1 oral pellet formulation
Paediatric HIV
An all-oral treatment has been my dream for decades. Less than ten years ago we were still treating this disease with an arsenic derivative that killed 5% of all patients and now we have a treatment that is safe, effective, and simple.
Dr Victor Kande
from the National Sleeping Sickness Control Programme of the Democratic Republic of Congo, screening villagers for sleeping sickness in Lwano village, DRC.
Sleeping sickness
I am very grateful to the health workers for the care and treatment offered to my son. My only worry now is how to control the continuous pain associated with the daily treatment injections.
Lwalatta Loteroi
father to Lorus Tuliamuk, a three-year-old receiving treatment at the Kacheliba District Hospital in West Pokot County, Kenya.
Leishmaniasis
Since there’s now a treatment, it’s time for those who haven’t taken the test to take it. I tell this to everyone, because health is so important.
José Fermín Pérez Barbosa
a farmer in Tamuría, Casanare district, Colombia.
Chagas
Every day, more people are infected than put on treatment. Hepatitis C is the 'silent epidemic' because people are unaware of their infection and go untreated for years. This is the challenge we are addressing.
Sasikala Siva
Clinical Project Manager in Kuala Lumpur, Malaysia, is a key figure in ensuring DNDi’s hepatitis C clinical trials run smoothly. Pictured here, she is showing her support for the test and treat #dontignorewhatucantc campaign.
Hepatitis C Virus

2018 key achievements

2018 was a milestone year for DNDi. We celebrated turning 15 by delivering a new sleeping sickness medicine, and seeing our sister organization, the Global Antibiotic Research & Development Partnership, go independent. We also made important progress in the development of other new treatments for neglected patients.

Dr Victor Kande

A doctor’s dream: an all-oral treatment for sleeping sickness

Read the full story
I’ve dedicated my life as a doctor to sleeping sickness. An all-oral treatment has been a dream of mine for decades. Fexinidazole comes as a simple pill: this is a huge leap in how we can tackle this deadly disease.
Dr Victor Kande
National Sleeping Sickness Control Programme, DRC
GARDP Board Chair

Global Antibiotic Research & Development Partnership (GARDP) independent after DNDi incubation

Read the full story
GARDP’s provenance from WHO and DNDi, and its significant progress in the last three years have positioned it well to play a key role in helping bring new antibacterials to market.
Professor Ramanan Laxminarayan
GARDP Board Chair
Executive Director, DNDi

New, affordable hepatitis C combination treatment shows 97% cure rate

Read the full story
The results indicate that the ravidasvir/sofosbuvir combination is comparable to the very best hepatitis C therapies available today, but it is priced affordably and could allow an alternative option in countries excluded from pharmaceutical company access programmes.
Dr Bernard Pécoul
Executive Director, DNDi

2018 in numbers

R&d portfolio
45
R&D projects
20
‘new chemical entities’ in DNDi’s drug development pipeline
344,642
chemical compounds screened for new drug potential – double the number in 2017!
Clinical trials
21
clinical trials in 7 disease areas at 50 sites in 16 countries
2,547
patients enrolled in active DNDi clinical studies
Strengthening capacities
565
people trained to support clinical research in Africa, Asia, and Latin America
Access to medicines
5
new national or global treatment policies & guidelines supported for sleeping sickness, leishmaniasis, and Chagas disease
Support received
€66.4 million
in multi-year funds secured for DNDi & GARDP
€20.2 million
in-kind contributions from partners – triple the value in 2017
Sharing knowledge
26
peer-reviewed scientific publications on DNDi research
85%
open-access peer-reviewed scientific publications on DNDi's research

Diseases & projects

Sleeping sickness
An all-oral treatment has been my dream for decades. Less than ten years ago we were still treating this disease with an arsenic derivative that killed 5% of all patients and now we have a treatment that is safe, effective, and simple.
Dr Victor Kande
from the National Sleeping Sickness Control Programme of the Democratic Republic of Congo.
Sleeping sickness
Leishmaniasis
There is a huge lack of information on the disease that leads to the use of several things to get cured, such as burned oil from cars. The scars are very ugly, so there is lots of stigma and discrimination faced by patients.
Ana Marilus Reyes Morales
whose two children have cutaneous leishmaniasis, Ancas, Peru. It takes them 12 hours to get to the hospital to receive treatment.
Leishmaniasis
Chagas
Since there’s now a treatment, it’s time for those who haven’t taken the test to take it. I tell this to everyone, because health is so important.
José Fermín Pérez Barbosa
a farmer in Tamuría, Casanare district, Colombia.
Chagas
Mycetoma
Patients like AbdelLatif are typically from poor, rural areas with limited health care access, so they usually seek diagnosis very late, when the disease is advanced and harder to treat.
Dr Dania Zaid
a doctor at the Mycetoma Research Centre (MRC), Khartoum, Sudan, on AbdelLatif AbdelRahim, a teenager from Darfur.
Mycetoma
Paediatric HIV
At the moment my daughter is doing well, the capsules are working good and are easy to use after the nurse showed me how to use them.
Jacklyne Kabakama
23, with her daughter in Kihara village, a rural area near Fort Portal, Uganda.
Paediatric HIV
Filarial diseases
Sometimes I cry all night, sometimes from suffering, sometimes from misery, and sometimes from poverty… my heart hurts from my lack of hope. I live a life of suffering.
Gertride Mapuani
a 61-year-old with river blindness, divorced and thrown out of her house by her husband because of the disease, in Babagulu village, Democratic Republic of Congo.
Filarial diseases
Hepatitis C
Every day, more people are infected than put on treatment. Hepatitis C is the 'silent epidemic' because people are unaware of their infection and go untreated for years. This is the challenge we are addressing.
Sasikala Siva
Clinical Project Manager in Kuala Lumpur, Malaysia, is a key figure in ensuring DNDi’s hepatitis C clinical trials run smoothly. Pictured here, she is showing her support for the test and treat #dontignorewhatucantc campaign.
Hepatitis C

2018 R&D highlights

Select a stage of development

Discovery

DNDi works with partners to screen millions of chemical compounds. Promising compounds are evaluated and optimized to produce just one or two drug candidates with potential.

Translation

DNDi and partners assess drug candidates for safety and develop compounds into medicines that can be given to patients. Drugs are first tested in a small number of healthy volunteers, followed by studies with a small number of patients to establish therapeutic dosing levels.

Clinical Development

With partners, DNDi conducts large-scale clinical trials with people affected by the disease, to confirm the new drug’s safety and efficacy.

Implementation & treatment access

DNDi supports dossier preparation for drug regulatory review and national registration, collects additional data on the use of new drugs in every-day clinical contexts, and works with health ministries and affected communities to tackle barriers to accessing treatment.

New collaboration to identify drug candidates Details

In March, DNDi began a collaboration with GlaxoSmithKline and the University of Dundee Drug Discovery Unit to discover new pre-clinical drug candidates targeting leishmaniasis and Chagas disease.

Open-source, virtual drug discovery projects gain momentum Details

The Mycetoma Open Source (MycetOS) project was launched by the University of Sydney, Erasmus MC, and DNDi, using an open source approach to discover potential treatments for mycetoma. DNDi’s Open Synthesis Network, which engages medicinal chemistry students in research for neglected diseases, expanded to more than 20 participating institutions by year end.

Eighth company joins DNDi NTD Drug Booster Details

The NTD Drug Discovery Booster enables more efficient screening of potential drug compounds, while benefiting from access to pharmaceutical partners’ compound libraries. In 2018, Astellas (Japan) joined the Booster, which, by the end of the year, had produced six series that have progressed to proof-of-concept studies for leishmaniasis and Chagas disease.

Potential new drugs for visceral leishmaniasis progress to Phase I Details

In a bid to radically transform patient therapy, from today’s complex and toxic treatments to patient-friendly, simple oral therapies, DNDi has built an unprecedented portfolio of oral drug candidates with donors and partners from industry and academia. Two of these – DNDI-0690 and DNDI-6148 – are now progressing to Phase I studies, to start in 2019.

Emodepside and TylAMac complete Phase I testing Details

Two Phase I studies in healthy volunteers for potentially macrofilaricidal drugs were successfully completed for emodepside (Bayer) and the antibiotic TylAMac (AbbVie). Phase II studies are planned.

Potential Chagas drug candidate from Daiichi Sankyo project Details

A project milestone was reached with the proven efficacy of a new compound against Chagas disease, which the partners hope to progress to the next stage of pre-clinical research in 2019.

Hepatitis C drug combination shows 97% cure rate Details

Interim results of a DNDi clinical trial showed the treatment combination of new drug candidate ravidasvir with sofosbuvir to be safe and effective, with very high cure rates for patients, including hard-to-treat cases.

Better VL treatment combination for East Africa? Details

Based on good results with combination therapies to treat visceral leishmaniasis (VL) in South Asia, a Phase III study started in April in Ethiopia, Kenya, Sudan, and Uganda to compare combination regimens of miltefosine and paromomycin with current treatment, which has side effects.

Putting the spotlight on PKDL Details

Results of a DNDi study in Bangladesh confirmed that post-kala-azar dermal leishmaniasis (PKDL) is a reservoir for transmission of VL and could thus threaten elimination efforts in South Asia. The findings highlight the importance of prompt diagnosis and treatment and the need for better drugs. A new PKDL treatment study began in Sudan in September.

World's first mycetoma clinical trial reaches interim analysis Details

The first-ever clinical trial for fungal mycetoma, underway in Sudan, enrolled 84 patients by year end, the recruitment threshold for interim analysis. The study is evaluating the efficacy of anti-fungal fosravuconazole with hopes for a more effective and affordable treatment for this most neglected of diseases.

Better treatment for HIV/VL co-infection Details

Results from a DNDi study in Ethiopia showed greater success with a treatment combination for people living with HIV who are co-infected with VL. These findings should pave the way for guideline change at national and international levels.

Shorter Chagas treatment could be just as effective Details

A two-week treatment course of benznidazole for adult patients with chronic Chagas disease showed similar efficacy and significantly fewer side effects than the standard eight-week treatment, according to a DNDi clinical trial in Bolivia.

Enrollment completed for single-dose sleeping sickness treatment Details

Following expansion of the acoziborole study to three new sites in two countries, DNDi successfully reached the target number of patients, with results expected in 2020.

Fexinidazole - paradigm shift for sleeping sickness treatment Details

In November, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a 'positive scientific opinion' of the first oral treatment for both stages of sleeping sickness, the result of a ten-year partnership between DNDi, Sanofi, and health ministry partners. Just 39 days later, the drug was registered in the Democratic Republic of Congo, where 70% of cases are found.

‘2-in-1’ formulation for children living with HIV proves effective Details

In February, interim results of DNDi’s implementation study showed that easy-to-take, heat-stable '2-in-1' pellets were well-tolerated and improved clinical outcomes in children living with HIV. DNDi continues to work on development of ‘4-in-1’ granules to be sprinkled on food or in milk, simpler and safer treatment for children too young to swallow pills.

Expanding access to Chagas diagnosis & treatment Details

DNDi and the Colombian Ministry of Health and Social Protection are piloting a simpler model of care to increase access to Chagas diagnosis and treatment, and a similar project is starting in Brazil with the Oswaldo Cruz Foundation and national stakeholder groups. In addition, funds from the sale of the priority review voucher awarded to Chemo Research for FDA registration of benznidazole are being devoted to improving patient access to diagnosis and treatment as outlined in the Global Access Framework for Chagas Disease by DNDi and the Fundación Mundo Sano.

Supporting Malaysian efforts for hepatitis C screening and treatment Details

FIND and DNDi teamed up in July to generate evidence to support policy change and scale-up of hepatitis C diagnosis and treatment throughout the Malaysian public health system. The project is decentralizing screening with rapid diagnostic tests and linking people to treatment, including in a DNDi clinical trial.

DNDi's clinical research in 2018

21 studies for 7 diseases, at 50 sites in 16 countries

Phase I

Leishmaniasis

  • DNDI-6148 (France) Starting in 2019
  • DNDI-0690 (UK) Starting in 2019

Filarial diseases

  • Emodepside single ascending dose for onchocerciasis (UK)
  • Emodepside multiple ascending doses – safety, tolerability, and pharmacokinetic studies (UK)
  • Emodepside relative bioavailability – immediate release tablets and solution (UK)
  • TylAMac (ABBV-4083) single ascending dose (AbbVie study sponsored by DNDi) (UK)
  • TylAMac (ABBV-4083) multiple ascending dose (AbbVie study sponsored by DNDi) (UK)
Phase IIa

Sleeping sickness

  • Acoziborole pivotal study in adults with stages 1 and 2 T.b. gambiense HAT (DRC)
  • Fexinidazole for T.b. rhodesiense stage 2 HAT (Uganda, Malawi) Starting in 2019

Cutaneous leishmaniasis

  • Thermotherapy & miltefosine combination proof-of-concept (Colombia, Peru)

Post-kala-azar dermal leishmaniasis

  • Short-course regimens for treatment of PKDL (India, Bangladesh)
  • Short-course regimens for treatment of PKDL (Sudan)

Chagas disease

  • Benznidazole new doses, improved treatment, and therapeutic associations (‘BENDITA’) (Bolivia)
  • Fexinidazole proof-of-concept (Spain)

Mycetoma

  • Fosravuconazole proof-of-concept for eumycetoma patients (Sudan)

Paediatric HIV

  • Abacavir/lamivudine/lopinavir/ritonavir as an easy-to-use paediatric formulation (‘LOLIPOP’) (Uganda) Starting in 2019
Phase IIb/III

Visceral leishmaniasis

  • Miltefosine/paromomycin for treatment of primary VL patients in Eastern Africa (Ethiopia, Kenya, Sudan, Uganda)

Post-kala-azar dermal leishmaniasis

  • Infectivity study of PKDL patients (Bangladesh)

HIV/VL

  • New treatments for HIV/VL co-infection (MSF study sponsored by DNDi) (India)
  • New treatments for HIV/VL co-infection (MSF study sponsored by DNDi) (Ethiopia)

Hepatitis C

  • Ravidasvir/sofosbuvir combination therapy (Malaysia, Thailand)
  • Ravidasvir bioequivalence study (Malaysia)
Phase IIIb/IV

Sleeping sickness

  • Fexinidazole for T.b. gambiense in adults and children, in- and out-patients (DRC, Guinea)

Post-kala-azar dermal leishmaniasis

  • Follow-up study of PKDL patients (India)

Paediatric HIV

  • Lopinavir/ritonavir pellets with dual NRTIs implementation study in infants and young children (‘LIVING’ study) (Kenya, Uganda, Tanzania)
Chagas Clinical Research Platform

Founded in 2009 in Uberaba, Brazil

459 members, from over 150 institutions and 24 countries

  • 8 clinical sites
  • 117 people trained
RedeLEISH

Founded in 2014 in Rio de Janeiro, Brazil

162 members from 83 institutions

  • 92 people trained
HAT Platform

Founded in 2005 in Kinshasa, Democratic Republic of Congo

120+ members from 20+ institutions

  • 13 clinical sites
  • 160 people trained
Leishmaniasis East Africa Platform

Founded in 2003 in Khartoum, Sudan

60 members from 20+ institutions

  • 5 clinical sites
  • 163 people trained

8 new treatments creating impact for neglected patients & 1 new antibiotics initiative

  • 2018 Fexinidazole: a paradigm shift for sleeping sickness

    First oral cure for all stages of sleeping sickness – shorter, easy-to-use medicine that brings treatment closer to patients and boosts elimination efforts.

    In partnership with Sanofi, the Human African Trypanosomiasis Platform, Doctors Without Borders (MSF), national sleeping sickness control programmes, and the World Health Organization (WHO).

    Read more
    2018 - Fexinidazole for sleeping sickness
  • 2018 Global Antibiotic Research & Development Partnership: new entity to fight antimicrobial resistance

    Following a three-year incubation by DNDi, the newly independent entity will develop and deliver new or improved antibiotic treatments, and support their sustainable access.

    In partnership with the World Health Organization.

    Read more
    2018 - Global Antibiotics Research & Development Partnership: new entity to fight antimicrobial resistance
  • 2016 More effective treatment for children with HIV who also have tuberculosis

    New hope for children co-infected with HIV and TB, after DNDi study shows ‘super-boosting’ an HIV drug means more effective TB treatment.

    In partnership with the Department of Health, South Africa

    Read more
    2016 - More effective treatment for children with HIV who also have tuberculosis
  • 2011 Easier and safer treatment for children with Chagas disease

    The first age-adapted paediatric dosage forms to make treatment of infants and children easier and safer.

    In partnership with LAFEPE in 2011, and with Fundación Mundo Sano and Insud/Exeltis/Laboratorio ELEA PHOENIX for a second source in 2018

    Read more
    2011 - Easier and safer treatment for children with Chagas disease
  • 2011 New VL treatments in South Asia

    New combination treatments to fend off resistance, improve patient care and support disease elimination.

    In partnership with South Asian health ministries, research institutes, NGOs, and WHO’s Special Programme for Research & Training in Tropical Diseases

    Read more
    2011 - in South Asia
  • 2010 A new VL combination in East Africa

    SSG&PM shown to be as safe and effective as the previous treatment, reducing treatment length by half and allowing more patients to be treated during outbreaks.

    In partnership with the Leishmaniasis East Africa Platform (LEAP), national leishmaniasis control programmes, MSF, and WHO

    Read more
    2010 - in East Africa
  • 2009 NECT: Safer, shorter treatment for sleeping sickness

    The first new treatment for sleeping sickness in 25 years finally ends the use of an arsenic-based derivative that kills 1 in 20 patients.

    In partnership with MSF, Epicentre, national sleeping sickness control programmes, and WHO

    Read more
    2009 - NECT: Safer, shorter treatment for sleeping sickness
  • 2008 ASMQ: a new combination treatment for malaria

    Thanks to a South-South technology transfer between Brazil and India, this new affordable, patent-free antimalarial has simplified malaria treatment.

    In partnership with Farmanguinhos/Fiocruz and Cipla

    Read more
    2008 - ASMQ: a new combination treatment for malaria
  • 2007 ASAQ: a new combination to simplify malaria treatment

    More than 500 million treatments of this affordable, patent-free antimalarial have been distributed since 2007.

    In partnership with Sanofi

    Read more
    2007 - ASAQ: a new combination to simplify malaria treatment
  • 2018 - Fexinidazole: a paradigm shift for sleeping sickness
    2018

    Fexinidazole: a paradigm shift for sleeping sickness

    Read more
  • 2018 - Global Antibiotics Research & Development Partnership: new entity to fight antimicrobial resistance
    2018

    Global Antibiotics Research & Development Partnership: new entity to fight antimicrobial resistance

    Read more
  • 2016 - More effective treatment for children with HIV who also have tuberculosis
    2016

    More effective treatment for children with HIV who also have tuberculosis

    Read more
  • 2011 - Easier and safer treatment for children with Chagas disease
    2011

    Easier and safer treatment for children with Chagas disease

    Read more
  • 2011 - in South Asia
    2011

    New VL treatments in South Asia

    Read more
  • 2010 - in East Africa
    2010

    A new VL combination in East Africa

    Read more
  • 2009 - NECT: Safer, shorter treatment for sleeping sickness
    2009

    NECT: Safer, shorter treatment for sleeping sickness

    Read more
  • 2008 - ASMQ: a new combination treatment for malaria
    2008

    ASMQ: a new combination treatment for malaria

    Read more
  • 2007 - ASAQ: a new combination to simplify malaria treatment
    2007

    ASAQ: a new combination to simplify malaria treatment

    Read more

Where we work

DNDi Research centers
  • New York
  • Rio de Janeiro
  • Geneva
  • Nairobi
  • Kinshasa
  • Cape Town
  • New Delhi
  • Kuala Lumpur
  • Tokyo
  • North America

    In 2018, DNDi North America continued its collaboration with the Center of Excellence for Chagas Disease in Los Angeles, publishing several joint articles describing barriers to access and models of care for people with Chagas, and supported DNDi’s global efforts to increase access to diagnosis and treatment, particularly in the Americas. In addition, the office garnered significant global media coverage of the approval of fexinidazole for sleeping sickness. In October, the office held a special event in New York City in celebration of DNDi’s 15-year anniversary, which raised awareness and funds for DNDi. Targeted advocacy was also carried out in the US, Canada, and the UN to advance policies that enable needs-driven R&D and affordable treatment access.

  • Latin America

    In 2018, the Latin America office completed two clinical studies for Chagas disease – one evaluating different benznidazole regimens in Bolivia and the other assessing the efficacy of fexinidazole – and completed patient enrollment in a clinical study on cutaneous leishmaniasis in Colombia and Peru. New projects were launched to increase access to Chagas diagnosis and treatment in Guatemala and Brazil, following the success of pilot projects in Colombia. DNDi also announced a collaboration with Insud Pharma and Pharco to increase access to affordable hepatitis C treatment in Latin America. The office also established official relations with the Pan-American Health Organization to strengthen collaborative efforts on these diseases as well as on innovation and access policies in the region and supported GARDP’s global observational study of newborns with sepsis.

  • East Africa

    In 2018, the Africa office supported implementation of clinical trials in leishmaniasis – with two new trials starting for shorter and simpler treatment for VL and for PKDL – as well as ongoing trials for mycetoma and HIV. The office also supported GARDP’s first clinical trial on the use of the antibiotic fosfomycin in newborns with sepsis. In October, more than 400 participants from 150 institutions in 40 countries joined DNDi for its 11th Partners Meeting in Kampala, Uganda on collaboration and R&D innovation. The Nairobi office also organized a Health Science Journalism Workshop for 18 journalists from 11 African countries, a first for DNDi in our objective to raise the profile of neglected patients’ needs. In addition, the office upgraded its quality standards ISO certification to the new ISO 9001:2015.

  • Democratic Republic of Congo

    The highlight for 2018 for the Kinshasa project office was the approval in the DRC of fexinidazole, the first oral treatment for sleeping sickness, a mere 39 days after the drug received a positive scientific opinion from the European Medicines Agency. The office also supported ongoing clinical studies in the DRC and Guinea testing both fexinidazole and acoziborole, as well as steering the Human African Trypanosomiasis Platform - EANETT Joint Scientific meeting in Uganda.

  • Southern Africa

    The joint DNDi-GARDP office continued to strengthen its collaborative efforts with the South African Medical Research Council (SAMRC). SAMRC provided 4 million Rand (~240,000 EUR) to further GARDP’s activities in South Africa to deliver affordable, new or improved antibiotic treatments for drug-resistant bacterial infections, beginning with neonatal sepsis and sexually-transmitted infections. GARDP launched a global observational study of babies with sepsis, with three South African sites, to guide development of new and improved antibiotic treatments for newborns. Recruitment of a team to provide support to the launch and execution of clinical trials in South Africa was also completed.

  • South Asia

    DNDi in India continues to support the Indian National Kala-azar Elimination Programme in building capacity to diagnose VL and PKDL, and by gathering evidence needed to respond to threats to the sustainable elimination of VL in the region. In 2018, DNDi in India partnered with MSF on a study for better treatment of HIV/VL co-infection in Bihar and completed recruitment for a clinical trial for shorter and safer PKDL treatments. The office also hosted the launch of GARDP’s global observational study to collect clinical information on treatment of babies with sepsis, to guide the development of new and improved antibiotic treatments for newborns.

  • South-East Asia

    DNDi’s Malaysia office supports the Malaysian Ministry of Health to enhance the country’s public health approach to hepatitis C and in 2018 partnered with the Foundation for Innovative New Diagnostics (FIND) to support the national plan to decentralize hepatitis C testing and treatment. The office has played a key role in DNDi’s Phase II/III clinical trial evaluating the effectiveness of a ravidasvir/ sofusbuvir combination to treat hepatitis C and presented the positive interim results to national stakeholders in Malaysia and Thailand in 2018. In addition, the office supported GARDP’s global observational study of newborns with sepsis.

  • Japan

    In 2018, key partnerships were secured with Japanese pharmaceutical partners: Astellas and Daiichi Sankyo RD Novare joined ongoing or new DNDi drug discovery projects, with support from Japan’s GHIT Fund, and a new screening project to discover potential compounds against antimicrobial-resistant bacteria was launched with Eisai and Takeda. Ongoing partnerships saw progress: a new drug candidate for VL, developed by Takeda with GHIT support, advanced into pre-clinical development. And DNDi’s Tokyo office supported the launch of JAGntd, a Japanese NTD network to promote Japan’s contribution to the global effort to control and eliminate NTDs.

How we worked in 2018:Collaborating, sharing our research, and preserving scientific independence

Some of the simple operating principles on which DNDi was established 15 years ago remain key to our work today: foster innovative, collaborative partnerships; promote the open sharing of research; and ensure diversified funding sources to preserve scientific independence, including alternative forms of support.

  • Growing number of partners As a collaborative organization working with partners on everything from R&D to advocacy, we count on our partners.
    Growing number of partners
  • Leveraging the number of people dedicated to DNDi research As a virtual research organization, DNDi subcontracts its research activities to partners and increases value for money by leveraging the number of staff dedicated to DNDi research who are not DNDi employees.
    Leveraging the number of people dedicated to dndi research
  • Generous in-kind contributions and collaborative funding In-kind contributions represent an important and growing element of the support DNDi receives from partners.
    Generous in-kind contributions and collaborative funding
  • Accessing ‘libraries’ of chemical compounds As part of our drug discovery efforts, we benefit from partners' chemical libraries, to screen and evaluate compounds for their potential as drug candidates.
    Accessing ‘libraries’ of chemical compounds
2018 financial information

2018 financial information

DNDi goes beyond the required audited financial statements in providing additional key financial performance indicators on expenditures and contributions.

Read financial statements
A word of thanks

A word of thanks

DNDi has now delivered eight new treatments for neglected patients and aims to deliver another eight to ten in the next five years, for a total of 16-18 new treatments by 2023. DNDi is deeply grateful for the support of all its donors, and for their commitment and collaboration since 2003.

Read the full list of thanks

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read Cookie Policy Close